Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Heart failure (HF) is a complex condition with significant risks of arterial and venous thrombosis due to blood, vascular, and flow abnormalities.
• Despite medical and device advancements, HF remains a major cause of death and hospitalization in the US, often linked to comorbidities like atrial fibrillation (AF) and stroke.
• Platelet activation and hypercoagulability are well-documented in HF patients, yet optimal antithrombotic strategies are unclear.

Purpose of the Study:

• To review the pathophysiology of coagulation abnormalities in heart failure.
• To examine the current evidence for anticoagulant and antiplatelet therapy in HF.
• To discuss the therapeutic implications of antithrombotic treatments in HF management.

Main Methods:

• Literature review of studies on coagulation abnormalities in HF.
• Analysis of clinical trial data and observational studies on anticoagulants in HF.
• Evaluation of research on antiplatelet agents in the context of HF.

Main Results:

• Anticoagulation is beneficial in HF with comorbidities like AF or prior venous thromboembolism.
• Evidence for anticoagulation in HF patients in sinus rhythm is less clear.
• There is a significant lack of data and consensus on the use of antiplatelet therapy in HF.

Conclusions:

• The role of antithrombotic therapy in HF requires further investigation, particularly for patients in sinus rhythm and those considered for antiplatelet agents.
• Understanding the pathophysiology of hypercoagulability in HF is crucial for developing targeted treatment strategies.
• Clinical guidelines for antithrombotic therapy in HF are needed to address current evidence gaps and improve patient outcomes.